Neurocrine Biosciences Inc vs Seagate Technology Holdings PLC — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Seagate Technology Holdings PLC trades at $897.99 (market cap $181.56B). The key difference: Seagate Technology Holdings PLC is far larger — about 10.4× Neurocrine Biosciences Inc's market cap, and Seagate Technology Holdings PLC pays a 0.37% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | STX | |
|---|---|---|
Market Cap | $17.40B | $181.56B |
Sector | Health | Technology |
52-Week High | $180.55 | $1.09K |
52-Week Low | $123.10 | $146.59 |
Enterprise Value | $16.49B | $184.59B |
Dividend Yield | — | 0.37% |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
Seagate Technology (STX) trades at $891.23, up 13.25% over the past 24 hours, with strong recent earnings beats and bullish analyst sentiment. The stock shows bearish technical signals but benefits from robust profitability metrics including a 21.6% net income margin and 96.27% ROE. Recent news highlights AI-driven storage demand as a key growth catalyst, with the company set to report Q2 2026 earnings on July 28, 2026.
Outlook remains positive due to AI infrastructure expansion and consistent earnings outperformance, though high valuation ratios and negative shareholder equity pose risks. Analyst consensus price target of $987.86 suggests upside potential, but investors should monitor debt levels and competitive pressures in the storage sector.
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →